I'm excited to present the results of our study "PRAISE-HFpEF DM: Glucagon-like Peptide-1 Receptor Agonist in Obese HFpEF with Type 2 Diabetes Mellitus" at the Late Breaking Clinical Trials/Clinical Science Session of the ESC-Heart Failure Congress in Lisbon, Portugal this May. Our study examines the clinical effectiveness of GLP-1RA in reducing hard clinical events (i.e,. heart failure hospitalization and cardiovascular death) in obese HFpEF patients with type 2 DM. I'm proud of our heart failure research team at Cleveland and external collaborators, marking our second late breaker study in the past 3 years. @MohamadKarnib5, Padmini Selvaganesan
Congratulations to the 7th @SCAI ELM class. Your graduation in 2026 will coincide with the 15th year anniversary - a special class! #SCAI2024
Press release: https://t.co/NriIWbgPz5
UPenn study shows that vanc-piptazo ⬆️ *creatinine* but actually causes a trend towards ⬇️Cystatin C. this dissociation between Cr vs. renal biomarker implies that piptazo is a pseudonephrotoxin that ⬇️ Cr secretion, w/o hurting the kidney (1/2) @Miano81
https://t.co/Zta5bC7K1v
@davidr_sweet I think this does a good job summarizing recent DOAC + antiplatelet trials, a space sometimes confusing to read about on my own https://t.co/9cX5hsE0rO
@jmacandcheese For the appropriate patient, I sometimes mention the risks of possible unnecessary workup or change in treatment or need for repeat lab tests due to lab test abnormality - have anecdotally heard of methimazole being started @drewjklein
https://t.co/F0M1hVZGRZ
Thank you for hosting a great tournament this year! Happy to contribute to the famously collegial relationship between nephrologists and cardiologists #lasix
And to celebrate the 10th #NephMadness, we are also giving prizes to the runners-up!
Congrats to these winners:
2nd Highest Med Student: Alexander Duncan
2nd Highest Resident: @rakimmitt
2nd Highest Fellow: @sshah713
2nd Highest Attending: @M_Abramson
*Top Fellow: @Ali_Azeem01
@MaxJordan_N @JeremyWVandive1 I like adding it early given mortality benefit as GDMT and for the K sparing effect, pitfalls are the delayed time to peak effect and risk of hyperK when you are no longer diureising aggressively - when discharging people with baseline CKD I check labs early post-DC
Excited to share our recent publication in @JournalGIM Exercise in Clinical Reasoning Series! Check it out!
https://t.co/ZWILnH9Yp0
Big thanks to @drewjklein, Dr. Bonifacino and Dr. Follansbee